bullish
Samsung Biologics (207940 KS): Near-Term Key Positive Catalysts
408 Views07 Jan 2023 15:41
SUMMARY
- Samsung Biologics (207940 KS) is expected to report strong Q4 results, with double-digit revenue growth. Partial operation of Plant 4 will impact profitability, which will be continued through H12023.
- The Chairman of the company has been selling shares, causing recent pullback in the stock, which should be considered as an attractive entry point.
- The long-term growth story remains intact, with all eyes being on upcoming conference where the company may unfold its capex plan amid stellar order book and industry demand.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Samsung Biologics (207940 KS): Strong Momentum in 2Q23- Revenue Up 33%; Net Profit Jumps 22%27 Jul 2023
- Samsung Biologics (207940 KS): Slow Start of 2023; Stronger Growth in H2; 2023 Guidance Raised27 Apr 2023
- Samsung Biologics (207940 KS): 2022 Revenue Surpassed KRW3T; Strong Growth Momentum to Continue31 Jan 2023
- Samsung Biologics (207940 KS): Near-Term Key Positive Catalysts07 Jan 2023
- Samsung Biologics (207940 KS): Record-High Semi-Annual Revenue Exceeding KRW1 Trillion29 Jul 2022
- Samsung Biologics (207940 KS): Well-Positioned to Leap Forward Without Biogen Deal20 Jan 2022
x